To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...

Novel lipid-lowering therapies such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) can dramatically lower low-density lipoprotein (LDL) and lipoprotein(a) levels, but are not ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

The related mechanisms were confirmed using lipid-loaded HepG2 cells together with PCSK9 siRNA, alirocumab (anti-PCSK9 antibody), and/or a p38-MAPK inhibitor. These findings confirmed that conditional ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

An article in Cell now describes a germline mutation in proprotein convertase subtilisin/kexin type 9 (PCSK9) that is associated with reduced survival in patients with breast cancer. Inhibition of ...

“This one is cool because the mechanism is pretty different from statins and PCSK9 inhibitors,” says Khera. “It can lower the LDL even if patients don’t have any LDL receptors. It has the ...

(NYSE:MRK) is developing an oral PCSK9 inhibitor, enlicitide ... which brings a new mechanism of action for treating wet AMD and diabetic macular edema, a condition with significant unmet need.

so they don’t have that same effect of causing liver damage. PCSK9 inhibitors are a new class of medications that may be available to patients to help reduce their cholesterol. By inhibiting a ...